An overview of FDA-approved new molecular entities: 1827-2013.
about
Pharmacogenomics in the clinicX-ray crystallography over the past decade for novel drug discovery - where are we heading next?Zebrafish small molecule screens: Taking the phenotypic plungeElectronic Medical Record-Integrated Pharmacogenomics and Related Clinical Decision Support Concepts.A Computational Methodology to Overcome the Challenges Associated With the Search for Specific Enzyme Targets to Develop Drugs Against Leishmania major.Repurposing of rutin for the inhibition of norovirus replication.The 3,4-dioxygenated 5-hydroxy-4-aryl-quinolin-2(1H)-one alkaloids. Results of 20 years of research, uncovering a new family of natural products.A comprehensive study of the association between drug hepatotoxicity and daily dose, liver metabolism, and lipophilicity using 975 oral medications.PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms.Physical Studies of P450-P450 Interactions: Predicting Quaternary Structures of P450 Complexes in Membranes from Their X-ray Crystal Structures.Resolving the neural circuits of anxiety.Optimizing drug development in oncology by clinical trial simulation: Why and how?Analysis of FDA-approved imaging agents.Why regulatory indifference towards pharmaceutical pollution of the environment could be a missed opportunity in public health protection. a holistic view.Severe Delayed Cutaneous and Systemic Reactions to Drugs: A Global Perspective on the Science and Art of Current Practice.Evaluating physician awareness of common health care costs in the emergency department.Academic-Industrial Collaboration: Toward the Consilience of Two Solitudes.An overview of FDA-approved vaccines & their innovators.Toward a pharmacy curriculum theory: spiral integration for pharmacy education.Investigating the disposal of expired and unused medication in Riyadh, Saudi Arabia: a cross-sectional study.Research synergy and drug development: Bright stars in neighboring constellations.Availability and quality of illegitimate somatropin products obtained from the Internet.Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products.Marketing medicines: charting the rise of modern therapeutics through a systematic review of adverts in UK medical journals (1950-1980).A diverse suite of pharmaceuticals contaminates stream and riparian food webs
P2860
Q26782786-530F1850-81FE-43F6-9EB8-D89D86C79806Q26801307-C4C49D1E-BE5C-431A-A9B8-538ACE038C5DQ28073655-2A4BE76E-41C8-4B7E-9971-D488DCDC6F7DQ30234897-9CB668AA-2AAB-4E4D-AD12-4521FB657D0DQ33797941-E0C8BF36-2408-46ED-84D7-DE263B2F8F87Q35674963-BE0E5A91-7BC8-4722-B1BB-6E1E00D2FCD7Q36156035-D3DF0970-680B-433D-80FD-02106D347583Q36231948-8A19554A-7360-4D9C-A6E2-FBA05F99B464Q37481946-7F279212-78EF-4ECA-8161-72964486A6D9Q37611698-2DBBF6EC-00DB-4086-B723-E882A6E36B05Q38592633-F237C11B-6FC7-4204-B8BD-2AD37AC2F63BQ38675644-BE361577-0302-4851-B705-EC0A9131D28BQ38739939-A38B4FD4-67AE-4E80-9004-E0FEB765E501Q38849196-A267D534-4DBB-4CE6-B37E-B107C1548388Q39291741-C9B5307D-61E9-474F-8891-E9570DCBF661Q40142162-A3D7B592-9650-4538-910D-FA124E640FC9Q41923139-04948419-8CA8-4DC5-9168-805993BD3920Q41933543-F545E6DE-3ECF-49A7-AE01-BB5D5839B1D5Q42040147-FBEA7631-AD6A-457F-8E5C-48AC80903ECBQ43346700-2636653C-C9D6-45ED-8E62-5F47E42AB435Q47272242-6C9C47C1-99E0-42A4-87DD-D367022AEDF7Q48196852-DE1459D2-E510-4B44-9AE9-ED69E86AEC5DQ49887894-BF8291D3-AB45-417B-B997-893C99DC2175Q50015983-6364EAFE-C47F-4C59-A915-620BA6B20281Q58608169-2DDAF9BC-6E8B-470D-9FDD-389041D0BAF4
P2860
An overview of FDA-approved new molecular entities: 1827-2013.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
An overview of FDA-approved new molecular entities: 1827-2013.
@ast
An overview of FDA-approved new molecular entities: 1827-2013.
@en
An overview of FDA-approved new molecular entities: 1827-2013.
@nl
type
label
An overview of FDA-approved new molecular entities: 1827-2013.
@ast
An overview of FDA-approved new molecular entities: 1827-2013.
@en
An overview of FDA-approved new molecular entities: 1827-2013.
@nl
prefLabel
An overview of FDA-approved new molecular entities: 1827-2013.
@ast
An overview of FDA-approved new molecular entities: 1827-2013.
@en
An overview of FDA-approved new molecular entities: 1827-2013.
@nl
P2093
P1433
P1476
An overview of FDA-approved new molecular entities: 1827-2013.
@en
P2093
Austin Haynesworth
Denton Hoyer
Sarah L Kinch
P304
P356
10.1016/J.DRUDIS.2014.03.018
P577
2014-03-26T00:00:00Z